Canandaigua National Corp decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.3% during the 1st quarter, Holdings Channel.com reports. The fund owned 8,321 shares of the medical research company’s stock after selling 199 shares during the period. Canandaigua National Corp’s holdings in Thermo Fisher Scientific were worth $3,798,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in TMO. Annapolis Financial Services LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $26,000. ShoreHaven Wealth Partners LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $28,000. Dimension Capital Management LLC acquired a new stake in Thermo Fisher Scientific in the 3rd quarter valued at $31,000. Larson Financial Group LLC increased its holdings in Thermo Fisher Scientific by 38.5% in the 4th quarter. Larson Financial Group LLC now owns 72 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 20 shares in the last quarter. Finally, Oder Investment Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at about $34,000. 87.17% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have recently commented on TMO shares. Stifel Nicolaus increased their price target on shares of Thermo Fisher Scientific from $530.00 to $600.00 and gave the stock a “buy” rating in a research report on Tuesday, February 2nd. Credit Suisse Group raised their price target on shares of Thermo Fisher Scientific from $556.00 to $580.00 in a research note on Tuesday, January 12th. Morgan Stanley raised their price objective on shares of Thermo Fisher Scientific from $535.00 to $575.00 and gave the company an “overweight” rating in a research note on Tuesday, February 2nd. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lowered shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $550.00 to $500.00 in a research note on Wednesday, December 16th. Finally, UBS Group decreased their price target on shares of Thermo Fisher Scientific from $588.00 to $560.00 and set a “buy” rating on the stock in a research report on Monday, March 29th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus price target of $524.45.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Sunday, January 31st. The medical research company reported $7.09 EPS for the quarter, topping analysts’ consensus estimates of $6.56 by $0.53. Thermo Fisher Scientific had a net margin of 17.12% and a return on equity of 21.35%. The company had revenue of $10.55 billion for the quarter, compared to analysts’ expectations of $9.53 billion. During the same quarter in the previous year, the firm posted $3.55 EPS. Thermo Fisher Scientific’s revenue was up 54.5% on a year-over-year basis. Equities analysts predict that Thermo Fisher Scientific Inc. will post 19.03 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 16th. Investors of record on Tuesday, March 16th will be given a $0.26 dividend. The ex-dividend date is Monday, March 15th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.22. This represents a $1.04 annualized dividend and a yield of 0.22%. Thermo Fisher Scientific’s payout ratio is 8.42%.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Article: What are the Benefits of Index Funds?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.